GYRE THERAPEUTICS, INC.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
GYRE$4.23-9.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Convertible Preferred Stock and Equity
(In thousands, except share amounts)
| Convertible Preferred Stock · Common Stock · AdditionalPaid-In · Statutory · Retained Earnings · AccumulatedOtherComprehensive · Total Gyre Stockholders’ Equity · Non-controlling · TotalEquity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital · Reserve · (Accumulated Deficit) · Income (Loss) · (Deficit) · Interest | |||||||||||
| Balances as of December 31, 2022 | — | $— | 63,588,119 | $64 | $32,795 | $2,660 | $7,395 | $(392) | $42,522 | $29,695 | $72,217 |
| Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions | 12,340 | 63,099 | 2,531,851 | 3 | 21,246 | — | — | — | 21,249 | — | 21,249 |
| Acquisition of minority interest | — | — | 10,463,627 | 10 | 7,845 | 438 | — | (415) | 7,878 | (7,878) | — |
| Issuance of Preferred Stock upon Private Placement | 811 | 1,426 | — | — | — | — | — | — | — | — | — |
| Stock-based compensation expense | — | — | — | — | 6,127 | — | — | — | 6,127 | 1,154 | 7,281 |
| Stock options exercised | — | — | 12,019 | — | 166 | — | — | — | 166 | — | 166 |
| Foreign currency translation adjustment | — | — | — | — | — | — | — | (837) | (837) | (647) | (1,484) |
| Net (loss) income | — | — | — | — | — | — | (92,933) | — | (92,933) | 7,453 | (85,480) |
| Balances as of December 31, 2023 | 13,151 | 64,525 | 76,595,616 | 77 | 68,179 | 3,098 | (85,538) | (1,644) | (15,828) | 29,777 | 13,949 |
| Stock-based compensation expense | — | — | — | — | 831 | — | — | — | 831 | — | 831 |
| Stock options exercised | — | — | 874,328 | 1 | 1,864 | — | — | — | 1,865 | — | 1,865 |
| Convertible preferred stock conversion | (13,151) | (64,525) | 8,767,333 | 8 | 64,517 | — | — | — | 64,525 | — | 64,525 |
| Issuance of Common Stock upon ATM program | — | — | 70,267 | — | 773 | — | — | — | 773 | — | 773 |
| CVR Liability settlement | — | — | — | — | 30 | — | — | — | 30 | — | 30 |
| Deferred Financing Costs Amortization | — | — | — | — | (9) | — | — | — | (9) | — | (9) |
| Foreign currency translation adjustment | — | — | — | — | — | — | — | (953) | (953) | (507) | (1,460) |
| Net income | — | — | — | — | — | — | 12,085 | — | 12,085 | 5,813 | 17,898 |
| Balances as of December 31, 2024 | — | $— | 86,307,544 | $86 | $136,185 | $3,098 | $(73,453) | $(2,597) | $63,319 | $35,083 | $98,402 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.